ProCE Banner Activity

An Expert’s Guide to WCLC 2021: A Preview of the Top Abstracts

Conference Coverage
Clinical Thought
Experts highlight key studies being presented at the upcoming 2021 WCLC virtual meeting. The CCO WCLC Virtual Conference Coverage program will have the information you need to understand and integrate the latest lung cancer data into your clinical practice.

Released: September 07, 2021

Expiration: September 06, 2022

No longer available for credit.

Share

Faculty

Anne Chiang

Anne Chiang, MD, PhD

Associate Professor
Yale University School of Medicine
Deputy Chief Medical Officer
Chief Network Officer
Smilow Cancer Hopsital
New Haven, Connecticut

Thomas Stinchcombe

Thomas Stinchcombe, MD

Medical Oncologist
Thoracic Oncology Program
Duke University Medical Center
Durham, North Carolina

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Bayer Healthcare Pharma

Daiichi Sankyo, Inc.

Janssen administered by Scientific Affairs

Janssen Pharmaceutica NV

Millennium Pharmaceuticals Inc Subsidary of Takeda

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme

Faculty Disclosure

Primary Author

Anne Chiang, MD, PhD

Associate Professor
Yale University School of Medicine
Deputy Chief Medical Officer
Chief Network Officer
Smilow Cancer Hopsital
New Haven, Connecticut

Anne Chiang, MD, PhD, has disclosed that she has received fees for non-CME/CE services from AstraZeneca and Catalyst and funds for research support from AbbVie, Amgen, AstraZeneca, and Bristol-Myers Squibb.

Thomas Stinchcombe, MD

Medical Oncologist
Thoracic Oncology Program
Duke University Medical Center
Durham, North Carolina

Thomas Stinchcombe, MD, has disclosed that he has received consulting fees from AstraZeneca, Daiichi Sankyo, EMD Serono, Foundation Medicine, Genentech/Roche, Janssen Oncology, Lilly, Medtronic, Novartis, Pfizer, Puma Biotechnology, Regeneron, and Takeda and research support from Advaxis, AstraZeneca, Genentech/Roche, Takeda, and Regeneron (to institution).